annb0t
Top 20
LONDON, UK / ACCESSWIRE / March 30, 2022 / Patient recruitment in the pivotal GBM AGILE study for lead asset paxalisib remains on track, with data expected in CY23, to be followed by a potential regulatory filing, if data are positive. Recent C-suite appointments in the United States suggest an increased focus on commercialization, particularly in the US market. Second asset EVT801 has progressed to human studies, with the first patient enrolled in a Phase I trial in France in November 2021 and ...
>>> Read more: Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
>>> Read more: Kazia TherapeuticsTrust (KZIA): Several Upcoming Catalysts
